x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012775
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human PYCR1 protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | PYCR1 |
| UniProt No. | P32322 |
| Gene ID | 5831 |
| Gene Description | Mitochondrial pyrroline-5-carboxylate reductase 1 catalyzes the last step in proline biosynthesis. Research studies show that proline is a limiting amino acid to clear cell renal cell carcinoma. PYCR1 expression is induced in kidney cancer cells to compensate for the proline shortage and maintain cancer cell growth. Furthermore, PYCR1 knockdown inhibits ccRCC cell proliferation in the absence of proline, suggesting this enzyme as a potential cancer therapeutic target. In addition, breast cancer cells also express high levels of PYCR1. Proline is restrictive to invasive ductal breast carcinoma cells, indicating proline vulnerability in breast cancer formation. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
